This exciting grassroots initiative taps into the strengths and resources of communities in inner-city and metropolitan areas to provide effective therapy for hepatitis C virus (HCV)-positive people who inject drugs (PWIDs). Live meetings for small, community-based groups of healthcare professionals will offer medical and addiction-services specialists cutting-edge strategies to collaboratively reach and treat HCV-positive PWIDs. Balancing clinical data with real-world experience and insights, these educational events will give participants the opportunity to interact directly with HCV and harm-reduction experts as well as resources to use and share in the practice setting. Strong local HCV-care networks will help build bridges to HCV-infected PWIDs and allow these high-risk individuals access to the care they need and deserve.

Goals of this educational initiative:

Prepare community-based HCV treaters to provide effective therapy for HCV-positive people who inject PWIDs
Increase HCV testing and treatment of PWIDs through proactive risk identification and referral by addiction-services centers
Educate HCV-care specialists and addiction-services personnel regarding harm-reduction principles and prevention of HCV reinfection
Build linkage to HCV-care networks within local/regional systems, drive high treatment and high sustained viral response (SVR) rates, and decrease incidence of HCV infection/reinfection within PWID populations

"Elimination of HCV is possible, but awareness and referral of people who inject drugs is not enough. To truly make an impact, changes need to happen at the community level."

Stacey Trooskin, MD, PhD, MPH

Chief Medical Officer


Stacey Trooskin, MD, PhD, MPH - Course Chair
Chief Medical Officer
Director of Viral Hepatitis Programs
Jonathan Lax Treatment Center
Philadelphia FIGHT
Philadelphia, Pennsylvania

Richard R. Andrews, MD, MPH
Addiction Medicine Physician
Board-certified Family Medicine Physician
Former Co-Chair, National Task Force on Hepatitis B
Advisory Panel, Hep B United
President, Houston Viral Hepatitis Task Force
Houston, Texas

Gregory Felzien, MD, AAHIVS
Diplomat: Internal Medicine and Infectious Disease
Medical Advisor
Division of Medical and Clinical Services
Georgia Department of Public Health
Atlanta, Georgia

Christian B. Ramers, MD, MPH, FIDSA, AAHIVS
Medical Director, Laura Rodriguez Research Institute
Chief, Population Health
Director, Graduate Medical Education
Family Health Centers of San Diego
San Diego, California

previous contributors

Andrew I. Aronsohn, MD
Co-Principal Investigator, HepCCATT
Associate Professor of Medicine
Faculty, MacLean Center for Clinical Medical Ethics
Program Director, Transplant Hepatology Fellowship
University of Chicago Medicine
Chicago, Illinois

Andrew J. Muir, MD
Professor of Medicine
Chief, Division of Gastroenterology
Department of Medicine
Duke University School of Medicine
Durham, North Carolina

Beth A. Dunlap, MD
Addiction Medicine Physician
Northern Illinois Recovery Center
Crystal Lake, IL

Sherilyn Brinkley, CRNP
Nurse Practitioner/Program Manager
Clinical Services and Research, Viral Hepatitis Center
Johns Hopkins University School of Medicine
Baltimore, Maryland

Judith Feinberg, MD
Professor of Medicine, Infectious Diseases
West Virginia University School of Medicine
Morgantown, West Virginia
Vice Chair, HIV Medicine Association (HIVMA)
Arlington, Virginia

Jody Gilmore, MSN, CRNP
Nurse Practitioner
Coordinator, Viral Hepatitis Program
Penn Presbyterian Medical Center
Philadelphia, Pennsylvania

Kelly Cooper, MD, MPH
Director, Addiction Medicine
Norton Healthcare
Addiction Medicine Physician
ReVIDA Recovery Centers
Knoxville, Tennessee

Zonaira Gul, MD
Infectious Disease Specialist
Beckley Appalachian Regional Hospital
Raleigh General Hospital
Beckley, West Virginia

Alain H. Litwin, MD, MPH, MS
Vice Chair of Academics and Research
Department of Medicine
Greenville Health System (GHS)
Greenville, South Carolina

Brianna L. Norton, DO, MPH
Assistant Professor
Department of Medicine and Infectious Diseases
Montefiore Medical Center
Albert Einstein College of Medicine Bronx, New York

Andy Seaman, MD
Old Town Clinic / Central City Concern
Assistant Professor of Medicine
Oregon Health Sciences University
Portland, Oregon

Mark S. Sulkowski, MD
Medical Director, Viral Hepatitis Center
Professor of Medicine
Johns Hopkins Medicine
Baltimore, Maryland

Brianna Sustersic, MD
Senior Medical Director
Primary, Care, Central City Concern
Old Town Clinic
Portland, Oregon


Community-BASED HCV Treaters

Part 1: Keys to Successful Treatment of HCV in People Who Inject Drugs

Part 2: Anatomy of Addiction




Register for meetings in your area:

San diego, CA


Legacy Medical Group - Midwifery

Date: Thursday, August 22, 2019

Time: 12:30 PM – 1:30 PM

Legacy Medical Group - Midwifery
2800 N Vancouver Ave.
Group Space – First Floor, Room 111
Portland, OR 97227

Faculty: Andy Seaman, MD


Atlanta, GA


Houston, TX


want to become part of bridge hcv?

become a participating member

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form :(

attend a meeting near you

Thank you! Your submission has been received!

Oops! Something went wrong while submitting the form :(


Continuing Medical Education (CME) INFORMATION

Community-BASED HCV Treaters

Target Audience

This educational initiative is intended for primary care, community HCV treaters, hepatologists, gastroenterologists, infectious disease specialists, as well as non-clinical office staff.

learning objectives

Upon completion of this program, HCV Treaters will be better able to:


Target Audience

This educational initiative is intended for addiction services/substance use disorder providers, medication-assisted treatment (MAT) providers, social workers, case managers, peer educators, peer advocates, as well as clinical and non-clinical office staff.

learning objectives

Upon completion of this program, addiction-services specialists will be better able to:

This activity is jointly provided by Purdue University College of Pharmacy and Integritas Communications.